Almirall, S.A. (FRA:E2Z)

Market Cap	2.27B -6.2%
Revenue (ttm)	1.16B +9.8%
Net Income	59.13M +177.1%
EPS	0.28 +179.0%
Shares Out	n/a
PE Ratio	38.45
Forward PE	22.42
Dividend	0.15 (1.44%)
Ex-Dividend Date	May 14, 2026

Volume	n/a
Open	10.54
Previous Close	10.66
Day's Range	10.54 - 10.54
52-Week Range	10.04 - 13.72
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 9, 2026

About Almirall

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal sys...

• Industry: Pharmaceutical Preparations
• Founded: 1943
• Employees: 2,097
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: E2Z

Financial Performance

In 2025, Almirall's revenue was 1.11 billion, an increase of 12.51% compared to the previous year's 990.63 million. Earnings were 46.15 million, an increase of 354.85%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 19, 2026

Data Sources Report a data error